Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SI | P14410 | 1/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7502549 | 0.77 | ALDH1A1 (0.48) | KMT2AMEN1ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL14013432 | 0.72 | SMN1; SMN2 (0.52) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL1986403 | 0.72 | CES2 (0.70) | KMT2AMEN1ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL13779317 | 0.71 | RAB9A (0.65) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL312393 | 0.71 | CES2 (0.68) | KMT2AMEN1ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL30512072 | 0.71 | CES2 (0.68) | KMT2AMEN1ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL7115992 | 0.70 | CYP19A1 (0.72) | ALDH1A1MGAMAMY1AGAASI | |
| Bromide SCHEMBL22749625 | 0.70 | CYP1A1 (0.60) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| Bromide SCHEMBL3899672 | 0.70 | NPC1 (0.75) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL73675 | 0.70 | CES2 (0.66) | KMT2AMEN1ALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197813-A1 | Heterocyclic Compounds as Sweetener Enhancers | REDPOINT BIO CORPORATION (US) | 2010-08-05 | — | — | US | claimed |
| US-7674831-B2 | Heterocyclic compounds as sweetener enhancers | REDPOINT BIO CORPORATION (US) | 2010-03-09 | — | — | US | claimed |
| US-20080249189-A1 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | REDPOINT BIO CORPORATION | 2008-10-09 | — | — | US | claimed |
| US-20100197813-A1 | Heterocyclic Compounds as Sweetener Enhancers | REDPOINT BIO CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197813-A1 | Heterocyclic Compounds as Sweetener Enhancers | REDPOINT BIO CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-7674831-B2 | Heterocyclic compounds as sweetener enhancers | REDPOINT BIO CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674831-B2 | Heterocyclic compounds as sweetener enhancers | REDPOINT BIO CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2061321-A2 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | Redpoint Bio Corporation (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080249189-A1 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | REDPOINT BIO CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249189-A1 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | REDPOINT BIO CORPORATION | 2008-10-09 | — | — | US | disclosed |
| WO-2008024364-A2 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | REDPOINT BIO CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249189-A1 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | TAS2R1, TAS1R1, TAS2R40 | KMT2A 1631/4885MEN1 903/4885NPC1 3113/4885 |
| US-20100197813-A1 | Heterocyclic Compounds as Sweetener Enhancers | TAS2R1, TAS1R1, TAS2R40 | KMT2A 1631/4885MEN1 903/4885NPC1 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.